Neurocutaneous Disorder Market Report 2025

The neurocutaneous disorder market size has grown strongly in recent years. It will grow from $2.05 billion in 2024 to $2.22 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. Growth in the historic period was driven by the rising prevalence of genetic disorders, increasing awareness of rare neurological conditions, greater adoption of diagnostic imaging, higher patient visits to specialty clinics, and growing clinical focus on pediatric neurology.

The neurocutaneous disorder market size is expected to see strong growth in the next few years. It will grow to $3.04 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. Growth in the forecast period is expected to be supported by increasing demand for targeted drug therapies, expansion of clinical trial activities for rare diseases, rising collaborations among research institutes, wider adoption of genetic testing services, and higher healthcare expenditure on neurological care. Key trends anticipated for the forecast period include advancements in genomic sequencing, innovation in gene therapy applications, increased investment in research and development for novel treatments, developments in digital health monitoring tools, and progress in biomarker-based diagnostics.

The growing prevalence of genetic disorders is anticipated to support the expansion of the neurocutaneous disorder market. Genetic disorders are medical conditions caused by changes or abnormalities in an individual's DNA, which may be inherited or occur spontaneously. Neurocutaneous disorders, including conditions such as tuberous sclerosis complex and neurofibromatosis, are caused by specific genetic mutations that affect both the nervous system and the skin, resulting in a combination of neurological symptoms and distinct dermatological signs. Advances in genetic testing and increased awareness are contributing to earlier diagnosis, which has led to a higher reported prevalence. For example, in November 2024, the Centers for Disease Control and Prevention, a government agency based in the United States, reported that approximately one in every thirty-three newborns in the country is born with a birth defect, many of which are linked to genetic causes. Therefore, the increasing incidence of genetic disorders is driving the growth of the neurocutaneous disorder market.

Leading companies within the neurocutaneous disorder market are prioritizing regulatory approvals to broaden their treatment offerings, improve patient outcomes, and meet growing demand for innovative therapies. Regulatory approvals refer to formal authorization from government authorities that permit the testing, marketing, or sale of a pharmaceutical product after confirming its safety and efficacy. For instance, in September 2025, AstraZeneca, a pharmaceutical and biotechnology company based in the United Kingdom, received approval from the Food and Drug Administration to market selumetinib, known commercially as Koselugo, for use in pediatric patients aged one year and older with neurofibromatosis type one who present with symptomatic and inoperable plexiform neurofibromas. This approval extends the previous indication, which covered children aged two years and older. Selumetinib is a MEK inhibitor that works by targeting the MAPK pathway, which plays a role in tumor development in neurofibromatosis type one. The treatment is administered orally twice daily and continued until disease progression or intolerable side effects arise. Common side effects include gastrointestinal issues, skin reactions, cardiac complications, and vision-related problems. This regulatory approval provides a vital treatment option for younger children affected by these complex and often disfiguring tumors, which are typically challenging to remove surgically.

In October 2022, Pasithea Therapeutics Corporation, a biotechnology company based in the United States, acquired AlloMek Therapeutics for an undisclosed amount. Through this acquisition, Pasithea seeks to expand its drug development pipeline focused on central nervous system disorders, with a particular emphasis on rare genetic conditions known as RASopathies. The deal is expected to support long-term growth and create potential synergies with Pasithea’s ongoing research in multiple sclerosis. AlloMek Therapeutics is a pharmaceutical company based in the United States that developed CIP-137401, a macrocyclic MEK inhibitor aimed at treating neurocutaneous disorders.

Major players in the neurocutaneous disorder market are Merck KGaA, AbbVie Inc., Sanofi S.A., Novartis AG, Recursion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific SE, Fosun Pharmaceutical Group Co. Ltd., ioMarin Pharmaceutical Inc., Simcere Pharmaceutical Group, Marinus Pharmaceuticals Inc., Inhibikase Therapeutics Inc., Healx Limited, NF2 Therapeutics Inc., NFlection Therapeutics Inc., Ovid Therapeutics Inc., CureAge Therapeutics, GW Pharmaceuticals plc.

North America was the largest region in the neurocutaneous disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurocutaneous disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neurocutaneous disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

A neurocutaneous disorder is a group of genetic conditions that affect both the nervous system and the skin, often present from birth due to mutations that disrupt normal cell growth and development. These disorders typically manifest with visible skin abnormalities such as birthmarks, lesions, or tumors, along with neurological complications including seizures, developmental delays, or cognitive impairments.

The primary types of neurocutaneous disorders include neurofibromatosis, tuberous sclerosis complex, Sturge-Weber syndrome, angiomatosis, and hypomelanosis of Ito. Neurofibromatosis encompasses NF1, NF2, and schwannomatosis, genetic conditions that cause tumor growth along nerves. Treatments include pharmacological therapy, surgical intervention, laser therapy, and physical or psychosocial support. These disorders affect various age groups, including pediatric patients (0-18 years), adults (19-65 years), and geriatric patients (65 years and above), and range in severity from mild to critical cases. Key end-users include hospitals, specialist clinics, homecare settings, research organizations, and pharmaceutical companies.

The neurocutaneous disorder market research report is one of a series of new reports that provides neurocutaneous disorder market statistics, including neurocutaneous disorder industry global market size, regional shares, competitors with a neurocutaneous disorder market share, detailed neurocutaneous disorder market segments, market trends and opportunities, and any further data you may need to thrive in the neurocutaneous disorder industry. This neurocutaneous disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurocutaneous disorder market includes revenues earned by entities by providing services, such as pharmacological treatment, medical consultation and diagnosis, psychological and behavioral support, and clinical trials and research participation. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.